Article Sidebar
Views pdf: 0
EVALUATION OF FIRST-LINE TREATMENT RESULTS OF ADVANCED CHOLANGIOCARCINOMA WITH GEMCITABINE – CISPLATIN CHEMOTHERAPY AT K HOSPITAL
Main Article Content
Abstract
Objective: To evaluate the initial treatment resultsand some toxicitie of Gemcitabine-Cisplatin chemotherapy in patients with advanced cholangiocarcinoma at K hospital. Patients and method: Retrospective and prospective study with longitudinal follow-up on 28 patients with advanced biliary tract cancer treated with Gemcitabine-Cisplatin chemotherapy at Tam Hiep Internal Medicine Department - K Hospital from January 2020 to August 2024. Results: 39% of patients experienced symptom relief after treatment. The disease control rate is 53.5%, the disease progression rate is 46.4%. The median progression-free survival is 7.2 ± 0.8 months (CI: 5.7–8.8). The incidence of erythrocytopenia in grade II is 25%, grade I, III is 14,29%. Leukopenia in grade III is 25%, grade IV is 7,14% (2 patients). Vomiting symptoms is 28.6% of patients. Liver toxicity in grade I is 25%, no kidney toxicity. Conclusion: The Gemcitabine-Cisplatin treatment regimen is suitable for patients with advanced biliary tract cancer, helping to prolong survival, good tolerance and improve the quality of life for patients.
Article Details
Keywords
: Biliary tract cancer, advanced stage, Gemcitabine-Cisplatin regimen, toxicity
References
2. Nguyễn Thị Bích Phượng (2021), "Đánh giá kết quả điều trị hóa chất bệnh nhân ung thư đường mật".
3. Trần Quế Sơn (2009), "Đặc điểm lâm sàng và kết quả phẫu thuật bệnh nhân ung thư đường mật trong gan tại bệnh viện Hữu Nghị Việt Đức".
4. Nịnh Thị Thảo, Vũ Hồng Thăng (2021), "Đánh giá kết quả bước đầu điều trị phác đồ gemcitabine kết hợp cisplatin trong ung thư đường mật giai đoạn muộn", Y học Việt Nam, 506, pp. 108-111.
5. Đoàn Thanh Tùng, Nguyễn Quang Nghĩa, and Nguyễn Tiến Quyết (2005), "Nghiên cứu các yếu tố ảnh hưởng đến thời gian sống sau phẫu thuật bệnh nhân ung thư đường mật trong gan", Y học Việt Nam, Số đặc biệt tháng 5, pp. 110-119.
6. Okusaka T, Nakachi K, Fukutomi A, et al. (2010), "Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan", Br J Cancer, 103 (4), pp. 469-74.
7. Sung H, Ferlay J, Siegel RL, et al. (2021), "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries", CA Cancer J Clin, 71 (3), pp. 209-249.
8. Valle JW, Furuse J, Jitlal M, et al. (2014), "Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials", Ann Oncol, 25 (2), pp. 391-8.